the staff of the Ridgewood blog
Ridgewood NJ, a full 18 months after the COVID crisis began, a big chunk of Americans still dramatically overestimate the risks of COVID. In a new Gallup poll, more than one third said the risk of being hospitalized if you’re not vaccinated is at least 50%. The actual number is between one and five percent!
Continue reading Democrats Are Still Far More Panic Stricken Than Republicans Over COVID
0the staff of the Ridgewood blog
Tallahassee Fl. with no lockdowns, mask mandates, school closures, or business limitations, the Florida COVID wave has crested and fallen dramatically in recent weeks.
Continue reading Florida COVID Wave Recedes As Fast As It Rose
the staff of the Ridgewood blog
KENILWORTH NJ, Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012. Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo. At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA), recruitment into the study is being stopped early due to these positive results. Merck plans to submit an application for Emergency Use Authorization (EUA) to the U.S. FDA as soon as possible based on these findings and plans to submit marketing applications to other regulatory bodies worldwide.
Continue reading Merck says its New COVID Antiviral Pill Reduces the Risk of Hospitalization
the staff of the Ridgewood blog
Washington DC, The Food and Drug Administration advisory committee on Friday rejected a proposal to distribute booster shots of Pfizer and BioNTech’s Covid-19 vaccines to the general public, paring back those plans to unanimously recommend the third shots to people age 65 and older and other vulnerable Americans.
Continue reading The FDA Say NO to Booster Shots , Except for Over 65 High Risk Individuals
the staff of the Ridgewood blog
Trenton NJ, Senator Joe Pennacchio will introduce new legislation that would treat recovered COVID-19 patients the same as those who have been vaccinated under any vaccine mandate or passport scheme that may be implemented.
the staff of the Ridgewood blog
Ridgewood NJ, England has abandoned its previously announced plan to implement a SARS-CoV-2 vaccine passport program by the end of this month that would have required people to show proof of vaccination to enter the country’s nightclubs and certain other crowded venues, UK Health Secretary Sajid Javid told the BBC on September 12. The announcement was made following opposition from some members of Parliament as well as representatives of the hospitality industry, who said such a program would create a burden for businesses and infringe on residents’ rights. Speaking on the Andrew Marr Show, Secretary Javid said the government decided against the passports after “properly” looking at the issue and determining other factors could help keep COVID-19 incidence down, including high vaccine uptake, testing, surveillance, and treatments. Some people suggested the passport proposal simply was a ruse to encourage young people to be vaccinated, although Secretary Javid hinted the government could reverse course again if the number of new cases rises. About 66% of the population of England is fully vaccinated. Several days prior to the announcement, British researchers published a paper in EClinicalMedicine casting doubt on whether vaccination passport programs would incentivize more people to get the shots and calling for additional research into the matter.
Eric Reyes
Ridgewood NJ, There are more than 100 clinical studies including more than 50,000 people from more than 2 dozen countries showing Ivermectin to be extremely safe and effective treating COVID. 63 of these studies were peer reviewed published placebo controlled studies. A meta-analysis of 14 of these peer reviewed published studies looked at high risk patients who were treated with ivermectin as prophylaxis (preventative) and they saw an 86% reduction in the combined end-point of COVID infections, number of hospitalizations, days hospitalized, the need for a ventilator, days on a ventilator, and deaths.
Continue reading Research say Not So Fast Writing Off Ivermectin
the staff of the Ridgewood blog
Hackensack NJ, Using ivermectin, an anti-parasitic drug, to treat or prevent COVID-19 is up there with swallowing bleach and blow drying your face, it does not work and can cause serious harm.
the staff of the Ridgewood blog
Washington DC, Dr. Anthony Fauci finally touted the effectiveness of monoclonal antibody treatments. Even Valley Health System provided a leading-edge therapy to patients at high-risk with mild to moderate COVID-19 infection and within 10 days of symptom onset. The treatment involves a single infusion of monoclonal antibodies, which are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens, such as viruses, back in January of 2021. This advancement highlights the broader potential of biotechnological innovations. You may avail yourself of Customized Cell Line Construction from Kyinno Biotech.
Continue reading Fauci a Day Late and A Dollar Short on Monoclonal Antibody Treatments
the staff of the Ridgewood blog
Ridgewood NJ, Less than half of Americans now have a favorable opinion of Dr. Anthony Fauci, we are not sure what took so long ? Most still want to follow the COVID-19 expert’s advice on dealing with the pandemic.
The latest Rasmussen Reports national telephone and online survey finds that 44% of American Adults have a favorable impression of Fauci, including 27% whose view of him is Very Favorable. Forty-two percent (42%) view Fauci unfavorably, including 29% whose opinion of him is Very Unfavorable. Fourteen percent (14%) are not sure. (To see survey question wording, click here.)
